VTRS · Viatris Inc
Price
Snapshot
50 fields · last close| Market Cap | $21.43B |
| P/E | — |
| Float | 1.16B |
| Beta | 0.89 |
| Volatility | 22.3% |
| Exchange | NASDAQ |
| Sector | Pharmaceuticals |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 80.8 |
| Price | 18.35 |
| Change | −1.63% |
| Prev Close | 18.66 |
| Open | 18.20 |
| Day Low | 18.15 |
| Day High | 18.66 |
| Avg Vol | 9 |
| Avg $ Vol | $158.8M |
| 52W High | 18.66 |
| 52W Low | 9.92 |
| 52W Pos | 96.4% |
| From High | −1.69% |
| From Low | +84.98% |
| Max DD 1Y | −19.65% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +4.07% |
| SMA 50 | +8.08% |
| SMA 200 | +17.63% |
| RSI (14) | 69.1 |
| Vol 30D | 23.4% |
| Vol 90D | 28.5% |
| 1Y Range | 10–19 |
| Daily bars | 536 |
| Perf Week | +5.75% |
| Perf Month | +8.90% |
| Perf Quarter | +9.80% |
| Perf Half Y | +27.08% |
| Perf Year | +86.92% |
| Perf YTD | +47.27% |
| Prev Day | −1.63% |
| Clavix | B+ |
| Debt / Eq | 0.98 |
| Curr Ratio | 1.38 |
| Int Cover | -0.4× |
| FCF Margin | 13.6% |
| Rev Growth | −3.0% |
| Profit | Unprofitable |
| Leverage | Moderate |
| Sector rank | 4 / 14 |
What VTRS does
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars.
It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health.
In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions.
It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands.
The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin.
Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Clavix risk grade
regraded every trading dayVTRS grades B+, 80.8 of 100. Steadiest on News Sentiment (68), most exposed on Price Stability (65, steady). 3 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 4 of 14 in Pharmaceuticals by Clavix score.
How rough the ride is
| VTRS | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.89 | 0.44 |
| Volatilityannualized | 22.3% | 10.9% |
| Max drawdown, past yearworst peak-to-trough fall | −19.7% | — |
| Typical daily movemedian absolute daily change | 1.04% | — |
| Days beyond ±3%of the last 252 sessions | 24 (10%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| VTRS | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.89 | 0.44 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low 67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| VTRS | |
|---|---|
| 1 week | +5.8% |
| 1 month | +8.9% |
| Year to date | +47.3% |
| 1 year | +86.9% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| VTRS | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 2 Aug |
| Average score0 most bearish, 100 most bullish | 66 |
| Bullish · bearisharticles above 60 · below 40 | 24 · 3 |
| Directionarticles whose tone is improving vs worsening | 24 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| VTRS | |
|---|---|
| Revenue growthyear over year | −3.0% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openViatris received U.S. FDA approval for RYZUMVI (phentolamine ophthalmic solution 0.75%) to treat presbyopia (age-related difficulty focusing on near objects) in adults. RYZUMVI was already FDA-approved to reverse pharmacologically-induced pupil dilation, and is the only product on the U.S. market with that approval.
Viatris received FDA approval for RYZUMVI (an eye drop called phentolamine ophthalmic solution 0.75%) to treat presbyopia, the age-related difficulty focusing on close objects, in adults. The product was already approved in the U.S. for reversing pupil dilation, and this expands its approved uses to a second condition.
Viatris (VTRS) will buy Pacira (PCRX) for $1.65 billion in cash, adding two pain treatments already on the market and one gene therapy still in clinical trials to grow its portfolio of non-opioid (non-narcotic) pain medicines.
Viatris (VTRS) agreed to acquire Pacira BioSciences (PCRX) for $1.65 billion in cash, gaining two already-marketed pain therapies and an early-stage gene therapy candidate to expand its non-opioid pain treatments.
Viatris is buying Pacira BioSciences for $1.65 billion to expand its pain-treatment business, adding Pacira's pain products and sales infrastructure alongside Viatris's own non-opioid program that is close to regulatory approval.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ZTS | Zoetis Inc | B+ | $31.87B | 12.55 | 0.70 | Compare |
| JAZZ | Jazz Pharmaceuticals PLC | A- | $13.65B | 14.51 | 0.38 | Compare |
| RPRX | Royalty Pharma PLC | A | $35.06B | 43.01 | 0.39 | Compare |
| CORT | Corcept Therapeutics Inc | C | $11.91B | 215.80 | 0.52 | Compare |
| ELAN | Elanco Animal Health Inc | B | $11.77B | — | 1.74 | Compare |
| CRNX | Crinetics Pharmaceuticals Inc | — | $9.01B | — | 0.45 | Compare |
| AXSM | Axsome Therapeutics Inc | B | $8.23B | — | 0.82 | Compare |
| MANE | Veradermics Inc | C+ | $4.55B | — | 0.44 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.